# US 2020/0262844 A1 · Rock kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0262844 A1
- Document ID: US20200262844A1
- Status: Published application
- Kind: A1
- Application number: 16/867,162
- Filed: 2020-05-05
- Published: 2020-08-20
- Earliest claimed: 2018-11-06
- Assignees: Cervello Therapeutics, LLC.
- Applicants: Cervello Therapeutics LLC
- Inventors: Matthew Randolph Lee; Anthony Joseph Varano, JR.; Thomas P. Bobinski
- Web page: https://patentgrep.com/patent/US20200262844A1

## CPC

- C07D 498/08: Bridged systems
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to compounds that inhibit ROCK activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.

## Claims

### Claim 1

A compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

A pharmaceutical composition, comprising an effective amount of a compound according to claim 1, and a pharmaceutically acceptable excipient.

### Claim 3 (depends on 1)

A method for inhibiting ROCK activity in a cell, comprising contacting the cell in which inhibition of ROCK activity is desired with a therapeutically effective amount of a compound of claim 1.

### Claim 4 (depends on 3)

The method of claim 3, wherein the contacting occurs in vivo.

### Claim 5 (depends on 3)

The method of claim 3, wherein the therapeutically effective amount of the compound is between about 0.01 to 300 mg/kg per day.

### Claim 6 (depends on 5)

The method of claim 5, wherein the therapeutically effective amount of the compound is between about 0.1 to 100 mg/kg per day.

### Claim 7 (depends on 1)

A method for treating a patient having cerebral cavernous malformation syndrome (CCM), comprising administering to the patient a therapeutically effective amount of a compound of claim 1, alone or combined with a pharmaceutically acceptable carrier, exicipient or diluents.

### Claim 8 (depends on 7)

The method of claim 7, wherein the therapeutically effective amount of the compound is between about 0.01 to 300 mg/kg per day.

### Claim 9 (depends on 8)

The method of claim 8, wherein the therapeutically effective amount of the compound is between about 0.1 to 100 mg/kg per day.

### Claim 10 (depends on 1)

A method of treating a cardiovascular disease associated with increased vasotension comprising administering a therapeutically effective amount of a compound of claim 1, alone or combined with a pharmaceutically acceptable carrier, exicipient or diluents, to a patient in need thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein the cardiovascular disease is hypertension, atherosclerosis, ischemic stroke, coronary vasospasm, cerebral vasospasm, angina or erectile dysfunction.

### Claim 12 (depends on 1)

A method of treating diseases involving elevated non-vascular smooth muscle contractility comprising administering a therapeutically effective amount of a compound of claim 1, alone or combined with a pharmaceutically acceptable carrier, exicipient or diluents, to a patient in need thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein the disease involving elevated non-vascular smooth muscle contractility is asthma or glaucoma.
